Alimentary Pharmacology & Therapeutics
Fecha de publicación: 08 July 2018
Autores: M. E. Joosse, M. A. Aardoom, P. Kemos, D. Turner, D. C. Wilson, S. Koletzko, J. Martin‐de‐Carpi, U. L. Fagerberg, C. Spray, C. Tzivinikos, M. Sladek, R. Shaoul, E. Roma‐Giannikou…
Background: Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease‐related inflammation and immune suppression, but data are limited due to their rare occurrence.